Comparative Pharmacology
Head-to-head clinical analysis: ESTRADIOL VALERATE ESTRADIOL VALERATE DIENOGEST versus ESTROVIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ESTRADIOL VALERATE ESTRADIOL VALERATE DIENOGEST versus ESTROVIS.
ESTRADIOL VALERATE; ESTRADIOL VALERATE; DIENOGEST vs ESTROVIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estradiol valerate is a prodrug of estradiol, an estrogen receptor agonist. Dienogest is a progestin with partial antiandrogenic activity, acting as a progesterone receptor agonist with antiovulatory and endometrial antiproliferative effects.
Estrovis (estropipate) acts by binding to estrogen receptors (ERα and ERβ), leading to activation of estrogen-responsive genes. It increases hepatic synthesis of sex hormone-binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins, and suppresses gonadotropin secretion via negative feedback on the hypothalamic-pituitary axis.
One tablet daily containing estradiol valerate 2 mg and dienogest 3 mg (oral).
1 mg orally once daily, continuous dosing cycle (no placebo week).
None Documented
None Documented
Estradiol valerate: Terminal half-life is approximately 13-14 hours for estradiol. Dienogest: Terminal half-life is about 10-11 hours. The combination allows for once-daily dosing with sustained hormone levels.
Terminal elimination half-life: 12-18 hours (mean 15 hours). Clinical context: Supports once-daily dosing; steady-state achieved within 3-5 days.
Estradiol valerate and dienogest: Urinary excretion accounts for approximately 50-60% of total clearance, primarily as glucuronide conjugates of estradiol and dienogest metabolites. Fecal/biliary excretion accounts for 30-40% of dienogest and its metabolites. For estradiol valerate, about 30% of metabolites are excreted in bile and feces.
Renal: 60-70% as glucuronide and sulfate conjugates; Fecal/biliary: 20-30% as conjugated metabolites.
Category D/X
Category C
Estrogen
Estrogen